Lipella Creates Oral Health Scientific Advisory Board

Lipella Pharmaceuticals (Nasdaq: LIPO), has appointed a five-member Scientific Advisory Board in oral health to focus on the development of LP-310 for the treatment of symptomatic oral lichen planus (OLP).

The Board will also provide guidance on the design of the company’s Phase 2a multicenter dose escalation study of LP-310 for IND submission.


  • Lipella’s Scientific Advisory Board is made up of highly regarded experts in oral medicine including Alessandro Villa (DDS, PhD, MPH), Michael Brennan (DDS, MHS), Kamal Al-Eryani (DDS, PhD), Vidya Sankar (DMD, MHS) and Hervé Y. Sroussi (DMD, PhD).
  • LP-310 is a proprietary liposomal oral rinse formulation of liposomal tacrolimus.
  • Tacrolimus is an FDA-approved drug. Lipella is working to develop tacrolimus via the 505(b)(2) regulatory pathway for oral cavity application. Lipella owns intellectual property rights to the drug’s formulation.

OLP is a chronic inflammatory condition that affects the mucous surfaces of the oral cavity. It  affects over six million Americans and represents great unmet medical need.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Lipella Creates Oral Health Scientific Advisory Board

Editor Prism MarketView